Hong Kong’s Strategic Foresight in Biotech Innovation for Global Healthcare Dominance

The recent Global Health Summit in Hong Kong, organized by Hong Kong Investment Corporation and New Frontier Group, gathered over 3,000 attendees with more than 150 speakers across 80 sessions focusing on medical and pharmaceutical advancements. The event highlighted Hong Kong’s potential to emerge as a premier international hub for biomedicine, biotech, and bioscience research, backed by unparalleled connectivity. Two key highlights from the summit included HKIC’s commitment to invest in a cluster of biotech firms, positioning Hong Kong at the forefront of Beijing’s drive to innovate and challenge the US in the global pharmaceutical market. HKIC, managing around $8…